OST-PTP Activators
OST-PTP Activators encompass a variety of chemical compounds that can indirectly augment the functional activity of OST-PTP through distinct signaling pathways. For instance, Forskolin and A23187 (Calcimycin) elevate intracellular levels of cAMP and calcium, respectively, thereby activating signaling cascades that can enhance the activity of OST-PTP. Forskolin activates protein kinase A, which can phosphorylate proteins in a manner that promotes OST-PTP activity. Similarly, A23187's elevation of calcium levels can lead to activation of calcium-dependent phosphatases that may upregulate OST-PTP activity. Genistein and Epigallocatechin gallate (OST-PTP Activators represent a curated collection of chemical entities designed to indirectly enhance the functional activity of OST-PTP through various cellular mechanisms. Forskolin, by raising intracellular cAMP, and A23187 (Calcimycin), by increasing calcium levels, activate PKA and calcium-dependent phosphatases, respectively, which can lead to an upsurge in OST-PTP activity by modifying its substrate affinity or alleviating inhibitory phosphorylations. Similarly, Genistein and Epigallocatechin gallate (EGCG) target tyrosine kinases, whose inhibition may relieve competitive phosphorylation on substrates of OST-PTP, thereby potentiating its phosphatase activity. Furthermore, PI3K inhibitors like LY294002 and Wortmannin, as well as MEK inhibitors PD98059 and U0126, can indirectly foster OST-PTP activation by diminishing the phosphorylation of proteins that, when phosphorylated, negatively regulate OST-PTP function. These inhibitors help to tip the intracellular signaling balance in favor of OST-PTP activation.
Sphingosine-1-phosphate (S1P) operates through its receptors to initiate signaling cascades that could facilitate OST-PTP activity, while Thapsigargin's role in manipulating calcium signaling can also indirectly benefit OST-PTP function. PMA, a PKC activator, through its diverse effects on cellular signaling, might contribute to the enhancement of OST-PTP by mitigating inhibitory cross-talk or phosphorylation events. Staurosporine, although a broad-spectrum kinase inhibitor, could paradoxically lead to increased OST-PTP activity by suppressing kinases that would otherwise hinder OST-PTP.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, increasing cyclic AMP (cAMP) levels, which in turn activate cAMP-dependent protein kinase A (PKA). PKA phosphorylation can lead to the functional activation of OST-PTP by influencing its substrate specificity or interaction with other proteins. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. While it is broad-spectrum, it can lead to increased activity of OST-PTP by inhibiting kinases that normally phosphorylate and inhibit OST-PTP, thus reducing competitive inhibition. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known for its inhibitory effect on certain tyrosine kinases. By inhibiting these kinases, EGCG might enhance OST-PTP activity by allowing it to act more freely on its substrates without competitive phosphorylation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin raises intracellular calcium levels by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). Elevated calcium levels can activate calcium-dependent protein tyrosine phosphatases, potentially enhancing the activity of OST-PTP. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P interacts with its receptors to activate intracellular signaling cascades, including those regulating phosphatase activity. S1P may enhance OST-PTP function by modulating these signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can increase OST-PTP activity by reducing PI3K/Akt pathway signaling, which often results in decreased phosphatase activity when active. By inhibiting PI3K, LY294002 allows OST-PTP to be more active. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, working similarly to LY294002. By inhibiting PI3K, Wortmannin may indirectly enhance OST-PTP activity by reducing the inhibitory phosphorylation of downstream targets. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of the MAPK/ERK pathway could result in increased OST-PTP activity by decreasing the phosphorylation state of proteins within this pathway that might regulate OST-PTP activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). Activation of PKC can influence multiple signaling pathways, some of which may indirectly increase the functional activity of OST-PTP through cross-talk or by reducing inhibitory phosphorylation events. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein acts as a tyrosine kinase inhibitor, which could lead to enhanced activity of OST-PTP by preventing phosphorylation that would compete with OST-PTP's phosphatase activity. | ||||||